nucleic
acid
aptam
minim
immunogen
high
chemic
synthesi
product
low
cost
high
chemic
stabil
compar
antibodi
howev
suscept
nucleas
degrad
rapid
excret
renal
filtrat
insuffici
bind
affin
hinder
develop
drug
candid
therapeut
applic
review
discuss
method
conquer
challeng
highlight
recent
develop
chemic
modif
technolog
advanc
may
enabl
earli
aptam
translat
clinic
therapeut
cap
unreact
free
oh
group
last
step
step
new
phosphit
oxid
correspond
phosphotriest
iodin
cycl
repeat
base
produc
requir
oligonucleotid
final
nucleic
acid
aptam
could
cleav
cpg
concentr
ammonium
hydroxid
protect
group
phosphat
heterocycl
base
could
remov
time
sever
group
isol
first
nucleic
acid
aptam
selex
systemat
evolut
ligand
exponenti
enrich
vitro
select
demarc
result
whether
techniqu
learn
tuerk
gold
ellington
szostak
respect
conform
complementar
aptam
bind
wide
rang
target
includ
small
metal
ion
organ
molecul
peptid
protein
virus
bacteria
whole
cell
even
target
within
live
anim
similar
bind
antibodi
antigen
bind
aptam
target
compar
bind
affin
specif
make
aptam
promis
class
therapeut
altern
antibodi
addit
nucleic
acid
aptam
minim
immunogen
high
chemic
synthesi
product
low
cost
high
chemic
stabil
draw
extens
attent
research
develop
aptam
therapeut
howev
suscept
nucleas
degrad
rapid
excret
renal
filtrat
sever
limit
practic
usag
aptam
mani
aptam
potent
activ
unaccept
short
halfliv
vivo
besid
bind
affin
specif
unmodifi
nucleic
acid
aptam
sometim
insuffici
success
implement
therapeut
agent
gener
high
qualiti
aptam
convent
selex
gener
figur
common
strategi
chemic
modif
nucleic
acid
aptam
purpos
among
modif
modif
termin
nucleic
acid
modif
phosphodiest
linkag
modif
sugar
ring
modif
base
end
cap
invert
thymidin
pegyl
common
strategi
chemic
modif
nucleic
acid
aptam
develop
clinic
therapeut
review
standard
synthet
method
solid
phase
phosphoramidit
chemistri
nucleic
acid
aptam
prepar
introduc
firstli
chemic
modif
strategi
aptam
resist
nucleas
degrad
improv
target
bind
affin
resist
renal
clearanc
summar
sequenti
among
modif
modif
termin
nucleic
acid
modif
phosphodiest
linkag
modif
sugar
ring
modif
base
end
cap
invert
thymidin
pegyl
common
strategi
chemic
modif
nucleic
acid
aptam
develop
clinic
therapeut
eg
pegaptanib
etc
excitingli
aptam
improv
bind
affin
gener
modif
base
substitut
two
nonbridg
phosphat
oxygen
atom
nucleic
acid
sulfur
replac
see
somam
walk
dna
aptam
synthes
classic
solid
phase
phosphoramidit
fourstep
process
autom
dna
synthes
fourstep
method
shown
figur
first
dmt
group
remov
deoxynucleosid
link
control
pore
glass
cpg
column
larg
excess
acid
solut
trichloroacet
acid
tca
could
use
deprotect
dmt
second
step
cycl
internucleotid
bond
call
phosphit
trimest
synthes
third
step
reaction
product
step
treat
cap
agent
cap
unreact
free
group
last
step
step
new
phosphit
oxid
correspond
phosphotriest
iodin
cycl
repeat
base
produc
requir
oligonucleotid
final
nucleic
acid
aptam
could
among
modif
modif
termin
nucleic
acid
modif
phosphodiest
linkag
modif
sugar
ring
modif
base
end
cap
invert
thymidin
pegyl
common
strategi
chemic
modif
nucleic
acid
aptam
develop
clinic
therapeut
review
standard
synthet
method
solid
phase
phosphoramidit
chemistri
nucleic
acid
aptam
prepar
introduc
firstli
chemic
modif
strategi
aptam
resist
nucleas
degrad
improv
target
bind
affin
resist
renal
clearanc
summar
sequenti
among
modif
modif
termin
nucleic
acid
modif
phosphodiest
linkag
modif
sugar
ring
modif
base
end
cap
invert
thymidin
pegyl
common
strategi
chemic
modif
nucleic
acid
aptam
develop
clinic
therapeut
eg
pegaptanib
etc
excitingli
aptam
improv
bind
affin
gener
modif
base
substitut
two
nonbridg
phosphat
oxygen
atom
nucleic
acid
sulfur
replac
see
somam
walk
dna
aptam
synthes
classic
solid
phase
phosphoramidit
fourstep
process
autom
dna
synthes
fourstep
method
shown
figur
first
dimethoxytriphenylmethyl
dmt
group
remov
deoxynucleosid
end
link
control
pore
glass
cpg
column
larg
excess
acid
solut
trichloroacet
acid
tca
could
use
deprotect
dmt
second
step
cycl
internucleotid
bond
call
phosphit
trimest
synthes
third
step
reaction
product
step
treat
cap
agent
figur
fourstep
phosphoramidit
oligodeoxynucleotid
synthesi
cycl
adapt
phosphoramidit
method
pioneer
marvin
caruth
earli
enhanc
applic
solidphas
technolog
autom
firmli
establish
method
choic
phosphoramidit
oligonucleotid
synthesi
proce
direct
opposit
direct
dna
biosynthesi
dna
replic
one
nucleotid
ad
per
synthesi
cycl
phosphoramidit
dna
synthesi
cycl
consist
seri
step
outlin
figur
present
applic
fourstep
method
common
part
progress
solid
phase
nucleic
acid
synthesi
field
chang
fundament
approach
r
purpos
shorten
aptam
nucleotid
length
gener
individu
lab
use
lab
scale
dna
rna
synthes
eg
expedit
sever
synthet
strategi
solidphas
synthesi
rna
report
among
combin
differ
couplingactiv
chemistri
protect
group
exocycl
amin
group
tertbutyldimethylsilyl
protect
ribos
group
combin
standard
protect
group
exocycl
amin
group
benzoyl
adenosin
acetyl
cytidin
isobutyryl
guanosin
wide
use
phosphoramidit
monom
usual
activ
ett
btt
figur
solid
support
rna
synthesi
polymer
support
cpg
differ
linker
pore
size
final
product
could
cleav
cpg
concentr
ammonium
hydroxid
protect
group
also
remov
time
phosphoramidit
method
pioneer
marvin
caruth
earli
enhanc
applic
solidphas
technolog
autom
firmli
establish
method
choic
phosphoramidit
oligonucleotid
synthesi
proce
direct
opposit
direct
dna
biosynthesi
dna
replic
one
nucleotid
ad
per
synthesi
cycl
phosphoramidit
dna
synthesi
cycl
consist
seri
step
outlin
figur
present
applic
fourstep
method
common
part
progress
solid
phase
nucleic
acid
synthesi
field
chang
fundament
approach
r
purpos
shorten
aptam
nucleotid
length
gener
individu
lab
use
lab
scale
dna
rna
synthes
eg
expedit
sever
synthet
strategi
solidphas
synthesi
rna
report
among
combin
differ
couplingactiv
chemistri
protect
group
hydroxyl
exocycl
amin
group
tertbutyldimethylsilyl
protect
ribos
hydroxyl
group
combin
standard
protect
group
exocycl
amin
group
benzoyl
adenosin
acetyl
cytidin
isobutyryl
guanosin
wide
use
phosphoramidit
monom
usual
activ
ett
btt
figur
solid
support
rna
synthesi
polymer
support
cpg
differ
linker
pore
size
final
product
could
cleav
cpg
concentr
ammonium
hydroxid
protect
group
also
remov
time
solidphas
rna
synthesi
via
phosphoramidit
method
adapt
rna
synthesi
group
protect
tbdm
tbutyldimethylsilyl
group
remov
treatment
fluorid
ion
termin
internucleotid
linkag
invers
test
selig
et
al
cap
invert
thymidin
also
common
strategi
among
aptam
diseas
therapi
ongo
complet
clinic
trial
research
suggest
dt
modif
could
increas
stabil
resist
aptam
human
serum
synthesi
dt
modifi
aptam
figur
need
modifi
cpg
first
nucleosid
attach
follow
chain
elong
standard
fashion
rna
synthesi
hydroxi
group
protect
tbdm
tbutyldimethylsilyl
group
remov
treatment
fluorid
ion
invers
test
selig
et
al
end
cap
invert
thymidin
also
common
strategi
among
aptam
diseas
therapi
ongo
complet
clinic
trial
research
suggest
invert
dt
modif
could
increas
stabil
resist
aptam
exonucleas
human
serum
synthesi
invert
dt
modifi
aptam
figur
need
modifi
cpg
hydroxyl
first
nucleosid
attach
follow
chain
elong
standard
fashion
solidphas
rna
synthesi
via
phosphoramidit
method
adapt
rna
synthesi
group
protect
tbdm
tbutyldimethylsilyl
group
remov
treatment
fluorid
ion
termin
internucleotid
linkag
invers
test
selig
et
al
cap
invert
thymidin
also
common
strategi
among
aptam
diseas
therapi
ongo
complet
clinic
trial
research
suggest
dt
modif
could
increas
stabil
resist
aptam
human
serum
synthesi
dt
modifi
aptam
figur
need
modifi
cpg
first
nucleosid
attach
follow
chain
elong
standard
fashion
way
biotin
figur
could
resist
activ
exonucleas
similar
invert
dt
modif
dougan
et
al
investig
biotinstreptavidin
conjug
thrombin
aptam
find
biotin
render
resist
exonucleas
blood
mous
rabbit
addit
biotinstreptavidin
conjug
slow
clearanc
rate
aptam
blood
circul
system
vivo
similar
biotin
approach
also
use
protect
dna
aptam
target
sar
coronaviru
helicas
h
fetal
bovin
serum
wherea
origin
aptam
sustain
half
time
way
figur
could
resist
activ
similar
dt
modif
dougan
et
al
investig
conjug
thrombin
aptam
find
render
resist
blood
mous
rabbit
addit
conjug
slow
clearanc
rate
aptam
blood
circul
system
vivo
similar
approach
also
use
protect
dna
aptam
target
sar
coronaviru
helicas
h
fetal
bovin
serum
wherea
origin
aptam
sustain
half
time
figur
structur
conjug
could
inhibit
activ
similar
dt
modif
addit
conjug
slow
clearanc
rate
blood
circul
system
vivo
modif
sugar
ribos
group
figur
pyrimidin
residu
avail
incorpor
enzymat
deriv
nucleic
acid
year
although
effect
improv
serum
halflif
modif
quickli
garner
favor
due
increas
coupl
effici
solidphas
synthesi
elimin
extra
deprotect
step
purif
bulki
modif
previous
use
postselect
modif
due
increas
nucleas
resist
high
duplex
melt
temperatur
could
seen
clinic
exampl
biotin
could
inhibit
activ
exonucleas
similar
invert
dt
modif
addit
biotin
conjug
slow
clearanc
rate
blood
circul
system
vivo
modif
sugar
fluoro
f
amino
nh
ribos
group
figur
pyrimidin
residu
avail
incorpor
enzymat
deriv
nucleic
acid
year
although
effect
improv
serum
halflif
f
modif
quickli
garner
favor
nh
due
increas
coupl
effici
solidphas
synthesi
elimin
extra
deprotect
step
nh
purif
bulki
omethyl
ome
modif
previous
use
postselect
modif
due
increas
nucleas
resist
high
duplex
melt
temperatur
could
seen
clinic
exampl
way
figur
could
resist
activ
similar
dt
modif
dougan
et
al
investig
conjug
thrombin
aptam
find
render
resist
blood
mous
rabbit
addit
conjug
slow
clearanc
rate
aptam
blood
circul
system
vivo
similar
approach
also
use
protect
dna
aptam
target
sar
coronaviru
helicas
h
fetal
bovin
serum
wherea
origin
aptam
sustain
half
time
figur
structur
conjug
could
inhibit
activ
similar
dt
modif
addit
conjug
slow
clearanc
rate
blood
circul
system
vivo
modif
sugar
ribos
group
figur
pyrimidin
residu
avail
incorpor
enzymat
deriv
nucleic
acid
year
although
effect
improv
serum
halflif
modif
quickli
garner
favor
due
increas
coupl
effici
solidphas
synthesi
elimin
extra
deprotect
step
purif
bulki
modif
previous
use
postselect
modif
due
increas
nucleas
resist
high
duplex
melt
temperatur
could
seen
clinic
exampl
figur
analog
ribonucleotid
methylen
linkag
c
sugar
ring
modif
show
great
resist
nucleas
increas
thermost
thu
could
use
gener
stabl
pair
darfeuil
et
al
also
found
lnadna
chimera
stabl
complex
transactiv
respons
tar
rna
abl
maintain
intact
structur
within
h
bovin
serum
shi
et
al
develop
new
lnadna
chimer
aptam
probe
proper
lna
incorpor
thymidin
cap
serum
stabil
origin
aptam
gradual
enhanc
specif
affin
perfectli
maintain
especi
aptam
pairlna
substitut
exhibit
tenfold
elev
stabil
serum
much
slower
clearanc
rate
mice
unlik
lna
structur
rigid
modif
increas
thermost
modifiedoligonucleotid
thu
protect
nucleas
degrad
cell
unlock
nucleic
acid
una
figur
bond
sugar
ring
absent
make
aptam
flexibl
due
natur
flexibl
una
could
allevi
strain
tight
loop
structur
pasternak
et
al
found
una
modif
loop
region
thrombin
target
dna
aptam
increas
thermodynam
stabil
howev
modif
within
gquartet
structur
unfavor
quadruplex
format
also
demonstr
una
could
place
mani
posit
without
affect
thrombinbind
affin
anticoagul
effici
aptam
found
modif
posit
sugar
ring
would
bring
differ
effect
thermost
base
molecular
gquadruplex
peng
et
al
discov
antihiv
phosphorothio
aptam
thrombinbind
aptam
substitut
guanin
g
adopt
anticonform
fg
could
maintain
quadruplex
conform
substitut
guanin
synconform
favor
importantli
two
fmodifi
thrombinbind
aptam
show
approxim
fourfold
increas
bind
affin
thrombin
sevenfold
higher
nucleas
resist
result
fluorodarabinonucl
acid
f
ana
figur
modif
suitabl
improv
biolog
physicochem
properti
dna
gquartet
cap
serum
stabil
origin
aptam
gradual
enhanc
specif
affin
perfectli
maintain
especi
aptam
pairlna
substitut
exhibit
tenfold
elev
stabil
serum
much
slower
clearanc
rate
mice
unlik
lna
structur
rigid
modif
increas
thermost
modifiedoligonucleotid
thu
protect
nucleas
degrad
cell
unlock
nucleic
acid
una
figur
bond
sugar
ring
absent
make
aptam
flexibl
due
natur
flexibl
una
could
allevi
strain
tight
loop
structur
pasternak
et
al
found
una
modif
loop
region
thrombin
target
dna
aptam
increas
thermodynam
stabil
howev
modif
within
gquartet
structur
unfavor
quadruplex
format
also
demonstr
una
could
place
mani
posit
without
affect
thrombinbind
affin
anticoagul
effici
aptam
found
modif
sugar
ring
would
bring
differ
effect
thermost
base
molecular
gquadruplex
peng
et
al
discov
antihiv
phosphorothio
aptam
thrombinbind
aptam
substitut
guanin
g
adopt
anticonform
could
maintain
quadruplex
conform
substitut
guanin
synconform
favor
importantli
two
thrombinbind
aptam
show
approxim
fourfold
increas
bind
affin
thrombin
sevenfold
higher
nucleas
resist
result
acid
ana
figur
modif
suitabl
improv
biolog
physicochem
properti
dna
gquartet
replac
phosphodiest
linkag
dna
methylphosphon
phosphorothio
analog
commonli
use
aptam
modif
thermodynam
studi
reveal
loss
neg
charg
phosphat
backbon
methylphosphon
analog
figur
destabil
gquadruplex
structur
ionic
radii
oligonucleotid
backbon
atom
also
impact
stabil
gquadruplex
structur
sacca
et
al
found
substitut
phosphat
backbon
atom
phosphorothio
analog
figur
might
influenc
thermal
stabil
gquadruplex
structur
molecularitydepend
manner
thermodynam
stabil
phosphodiest
linkag
thrombinbind
aptam
ggttggtgtggttgg
thiophosphoryl
substitut
differ
internucleotid
site
studi
complet
substitut
thiophosphoryl
oligonucleotid
limit
high
toxic
partial
substitut
maximum
thermal
stabil
select
evalu
stabil
condit
nucleas
dnase
hydrolysi
antithrombin
activ
blood
plasma
aptam
ggststsggtgtggststsgg
replac
phosphodiest
linkag
dna
methylphosphon
phosphorothio
analog
commonli
use
aptam
modif
thermodynam
studi
reveal
loss
neg
charg
phosphat
backbon
methylphosphon
analog
figur
destabil
gquadruplex
structur
ionic
radii
oligonucleotid
backbon
atom
also
impact
stabil
gquadruplex
structur
sacca
et
al
found
substitut
phosphat
backbon
atom
phosphorothio
analog
figur
might
influenc
thermal
stabil
gquadruplex
structur
molecularitydepend
manner
thermodynam
stabil
phosphodiest
linkag
thrombinbind
aptam
ggttggtgtggttgg
thiophosphoryl
substitut
differ
internucleotid
site
studi
complet
substitut
thiophosphoryl
oligonucleotid
limit
high
toxic
partial
substitut
maximum
thermal
stabil
select
evalu
stabil
condit
nucleas
dnase
hydrolysi
antithrombin
activ
blood
plasma
aptam
ggststsggtgtggststsgg
thiosubstitut
tt
loop
exhibit
similar
antithrombin
effici
unmodifi
aptam
better
resist
degrad
dna
nucleas
blood
serum
thiosubstitut
tt
loop
exhibit
similar
antithrombin
effici
unmodifi
aptam
better
resist
degrad
dna
nucleas
blood
serum
recent
phosphorodiothio
linkag
employ
stabil
phosphat
backbon
substitut
nonbridg
oxygen
atom
sulfur
could
give
rise
phosphorodithio
linkag
similar
natur
dna
achir
phosphoru
addit
report
substitut
dramat
improv
target
bind
affin
see
walk
replac
oligonucleotid
phosphodiest
linkag
triazol
linkag
shown
great
promis
triazol
analog
obtain
autom
phosphoramidit
synthesi
modifi
dinucleosid
block
click
reaction
azideand
alkynebear
nucleosid
figur
show
three
type
promis
triazol
internucleotid
modif
figur
analog
bore
dna
hybrid
affin
similar
origin
oligonucleotid
increas
resist
nucleas
cleavag
recent
phosphorodiothio
linkag
employ
stabil
phosphat
backbon
substitut
nonbridg
oxygen
atom
sulfur
could
give
rise
phosphorodithio
linkag
similar
natur
dna
achir
phosphoru
addit
report
substitut
dramat
improv
target
bind
affin
see
walk
replac
oligonucleotid
phosphodiest
linkag
triazol
linkag
shown
great
promis
triazol
analog
obtain
autom
phosphoramidit
synthesi
modifi
dinucleosid
block
click
reaction
azideand
alkynebear
nucleosid
figur
show
three
type
promis
triazol
internucleotid
modif
thiosubstitut
tt
loop
exhibit
similar
antithrombin
effici
unmodifi
aptam
better
resist
degrad
dna
nucleas
blood
serum
recent
phosphorodiothio
linkag
employ
stabil
phosphat
backbon
substitut
nonbridg
oxygen
atom
sulfur
could
give
rise
phosphorodithio
linkag
similar
natur
dna
achir
phosphoru
addit
report
substitut
dramat
improv
target
bind
affin
see
walk
replac
oligonucleotid
phosphodiest
linkag
triazol
linkag
shown
great
promis
triazol
analog
obtain
autom
phosphoramidit
synthesi
modifi
dinucleosid
block
click
reaction
azideand
alkynebear
nucleosid
figur
show
three
type
promis
triazol
internucleotid
modif
figur
analog
bore
dna
hybrid
affin
similar
origin
oligonucleotid
increas
resist
nucleas
cleavag
figur
analog
bore
dna
hybrid
affin
similar
origin
oligonucleotid
increas
resist
nucleas
cleavag
varizhuk
et
al
synthes
sever
new
oligonucleotid
analog
triazol
internucleotid
linkag
click
reaction
shown
figur
analog
bore
dna
hybrid
affin
similar
origin
oligonucleotid
increas
resist
nucleas
cleavag
later
varizhuk
et
al
synthes
seri
triazolemodifi
dna
aptam
structur
similar
thrombininhibit
gquadruplex
thrombinbind
aptam
test
secondari
structur
stabil
bind
affin
thrombin
anticoagul
effect
modif
central
loop
aptam
quadruplex
result
anticoagul
activ
similar
although
modif
fail
enhanc
thrombin
bind
affin
protect
aptam
nucleas
hydrolysi
thu
increas
stabil
novel
aptam
potent
thrombin
inhibitor
could
altern
known
anticoagul
drug
figur
may
display
high
resist
degrad
nucleas
retain
affin
target
base
sequenc
dform
aptam
lenantiomer
oligonucleotid
aptam
also
call
spiegelm
chemic
synthes
base
domain
approach
purschk
et
al
found
spiegelm
bound
stabl
acid
length
domain
bacteri
staphylococc
enterotoxin
b
ldna
spiegelm
show
compar
bind
affin
lpeptid
domain
slightli
reduc
affin
whole
bacteri
staphylococc
enterotoxin
b
protein
vitroselect
process
start
random
pool
oligonucleotid
spiegelm
dissoci
constant
kd
nm
gonadotropinreleas
hormon
gnrh
report
wlotzka
et
al
spiegelm
effect
antagonist
gnrh
chines
hamster
castrat
rat
model
besid
pegyl
spiegelm
show
pronounc
inhibit
activ
longer
plasma
halflif
toward
target
spiegelm
high
specif
affin
identifi
usag
spiegelm
technolog
leva
et
al
firstli
aptam
bind
dgnrh
kd
nm
isol
enantiom
synthes
result
spiegelm
similar
affin
daptam
mani
clinic
evalu
aptam
laptam
number
differ
strategi
chemic
modif
avail
enhanc
stabil
aptam
nucleas
tabl
among
modif
fluoro
omethylsubstitut
end
cap
invert
thymidin
common
strategi
chemic
modif
nucleic
acid
aptam
resist
nucleas
degrad
pronounc
inhibit
activ
longer
plasma
halflif
toward
target
spiegelm
high
specif
affin
identifi
usag
spiegelm
technolog
leva
et
al
firstli
aptam
bind
dgnrh
kd
nm
isol
enantiom
synthes
result
spiegelm
similar
affin
daptam
mani
clinic
evalu
aptam
laptam
number
differ
strategi
chemic
modif
avail
enhanc
stabil
aptam
nucleas
tabl
among
modif
end
cap
invert
thymidin
common
strategi
chemic
modif
nucleic
acid
aptam
resist
nucleas
degrad
strategi
applic
end
nucleic
acid
chain
termin
internucleotid
linkag
biotin
conjug
sugar
ring
nucleosid
even
stabil
backbon
modif
small
aptam
subject
rapid
excret
renal
clearanc
mainli
glomerular
filtrat
formul
bulki
moieti
enlarg
size
aptam
overcom
renal
filtrat
extend
circul
time
evid
cholesterol
derivat
end
aptam
form
cholesterololigonucleotid
cholodn
conjug
smidt
et
al
ad
cholesterol
end
oligonucleotid
odn
phosphat
spacer
figur
halftim
result
cholodn
min
plasma
consider
longer
unmodifi
odn
min
result
cholodn
link
lowdens
lipoprotein
ldl
form
cholodnldl
complex
turn
stabl
degrad
rat
serum
nucleas
cholodn
roughli
longer
plasma
halflif
unmodifi
odn
lee
cowork
modifi
nucleotidelong
f
pyrimidin
modifi
rna
aptam
cholesterol
form
cholesterolconjug
aptam
cholaptam
figur
effici
absorb
cell
inhibit
hepat
c
viru
rna
replic
cholaptam
toxic
vitro
vivo
induc
notabl
alter
gene
express
profil
includ
innat
immunerel
gene
moreov
administr
cholaptam
well
toler
mice
without
abnorm
observ
notic
cholesterol
conjug
show
longer
halflif
approxim
nine
time
lower
clearanc
rate
plasma
word
extend
durat
time
aptam
stay
plasma
thu
enhanc
stabil
aptam
expos
bodi
cholodn
roughli
longer
plasma
halflif
unmodifi
odn
lee
cowork
modifi
nucleotidelong
pyrimidin
modifi
rna
aptam
cholesterol
form
cholesterolconjug
aptam
cholaptam
figur
effici
absorb
cell
inhibit
hepat
c
viru
rna
replic
cholaptam
toxic
vitro
vivo
induc
notabl
alter
gene
express
profil
includ
innat
immunerel
gene
moreov
administr
cholaptam
well
toler
mice
without
abnorm
observ
notic
cholesterol
conjug
show
longer
halflif
approxim
nine
time
lower
clearanc
rate
plasma
word
extend
durat
time
aptam
stay
plasma
thu
enhanc
stabil
aptam
expos
bodi
willi
et
al
report
prepar
function
properti
nucleaseresist
vascular
endotheli
growth
factor
vegf
aptam
attach
liposom
bilay
lipid
group
result
liposomeanchor
aptam
maintain
high
bind
affin
vegf
moreov
resid
time
plasma
consider
improv
compar
origin
aptam
use
solid
phase
phosphoramidit
method
prepar
dialkylglycerol
dag
modifi
vegf
aptam
two
satur
unbranch
hydrocarbon
chain
attach
via
tetraethylen
glycol
linker
dag
phosphoramidit
synthes
seven
step
introduc
end
vegf
aptam
figur
afterward
dagmodifi
vegf
aptam
incorpor
bilay
liposom
result
aptam
improv
inhibitori
activ
toward
vegfinduc
endotheli
cell
prolifer
vitro
increas
vascular
permeabl
vivo
willi
et
al
report
prepar
function
properti
nucleaseresist
vascular
endotheli
growth
factor
vegf
aptam
attach
liposom
bilay
lipid
group
result
liposomeanchor
aptam
maintain
high
bind
affin
vegf
moreov
resid
time
plasma
consider
improv
compar
origin
aptam
use
solid
phase
phosphoramidit
method
prepar
dialkylglycerol
dag
modifi
vegf
aptam
two
satur
unbranch
hydrocarbon
chain
attach
via
tetraethylen
glycol
linker
dag
phosphoramidit
synthes
seven
step
introduc
vegf
aptam
figur
afterward
dagmodifi
vegf
aptam
incorpor
bilay
liposom
result
aptam
improv
inhibitori
activ
toward
vegfinduc
endotheli
cell
prolifer
vitro
increas
vascular
permeabl
vivo
figur
synthesi
dialkylglycerol
dag
modifi
vegf
aptam
adapt
liposomeanchor
aptam
maintain
high
bind
affin
vegf
moreov
plasma
resid
time
consider
improv
compar
origin
aptam
hoffmann
et
al
describ
pegyl
aminomodifi
oligonucleotid
use
nhydroxysuccinimid
nh
esteractiv
polyethylen
glycol
peg
wide
use
especi
manufactur
larg
quantiti
pegyl
oligonucleotid
follow
synthesi
twostep
deprotect
result
intermedi
aminomodifi
oligonucleotid
react
nhsesteractiv
peg
form
oligonucleotidepeg
conjug
figur
coupl
method
activ
figur
synthesi
dialkylglycerol
dag
modifi
vegf
aptam
adapt
liposomeanchor
aptam
maintain
high
bind
affin
vegf
moreov
plasma
resid
time
consider
improv
compar
origin
aptam
hoffmann
et
al
describ
pegyl
aminomodifi
oligonucleotid
use
nhydroxysuccinimid
nh
esteractiv
polyethylen
glycol
peg
wide
use
especi
manufactur
larg
quantiti
pegyl
oligonucleotid
follow
synthesi
twostep
deprotect
result
intermedi
aminomodifi
oligonucleotid
react
nhsesteractiv
peg
form
oligonucleotidepeg
conjug
figur
coupl
method
activ
pnitrophenyl
carbon
thiolmaleimid
coupl
could
also
use
choic
coupl
strategi
made
consider
follow
factor
compat
oligonucleotid
access
modifi
oligonucleotid
reactiv
activ
peg
react
function
site
oligonucleotid
one
dna
aptam
bind
specif
murin
extracellular
domain
program
death
protein
block
program
deathligand
interact
howev
unmodifi
dna
aptam
exhibit
short
vivo
halftim
h
owe
rapid
renal
filtrat
small
molecul
report
conjug
aptam
high
molecular
weight
peg
could
limit
rate
filtrat
extend
halflif
h
thu
modifi
termini
kda
peg
figur
pegyl
form
retain
abil
block
bind
significantli
suppress
growth
posit
colon
carcinoma
vivo
tabl
deprotect
pegyl
oligonucleotid
figur
addit
aminolink
oligonucleotid
pegyl
aminomodifi
oligonucleotid
kda
yshape
peg
n
adapt
aminomodifi
oligonucleotid
could
react
nhsesteractiv
peg
form
oligonucleotidepeg
conjug
conjug
aptam
high
molecular
weight
peg
could
limit
rate
filtrat
extend
halflif
h
figur
reaction
scheme
aptam
conjug
kda
polyethylen
glycol
peg
adapt
strategi
applic
figur
addit
aminolink
end
oligonucleotid
pegyl
aminomodifi
oligonucleotid
kda
yshape
peg
n
adapt
aminomodifi
oligonucleotid
could
react
nhsesteractiv
peg
form
oligonucleotidepeg
conjug
conjug
aptam
high
molecular
weight
peg
could
limit
rate
filtrat
extend
halflif
h
figur
addit
aminolink
oligonucleotid
pegyl
aminomodifi
oligonucleotid
kda
yshape
peg
n
adapt
aminomodifi
oligonucleotid
could
react
nhsesteractiv
peg
form
oligonucleotidepeg
conjug
conjug
aptam
high
molecular
weight
peg
could
limit
rate
filtrat
extend
halflif
h
figur
reaction
scheme
aptam
conjug
kda
polyethylen
glycol
peg
adapt
termin
pegyl
common
strategi
chemic
modif
nucleic
acid
aptam
resist
renal
clearanc
aptam
improv
bind
affin
gener
modif
base
aptam
singl
strand
dna
ggtggtggtggttgtggtg
gtggtgg
bind
nucleolin
protein
express
surfac
cancer
cell
recent
research
shown
nbenzylcarboxyamid
modif
figur
aptam
might
select
increas
target
affin
cancer
cell
normal
healthi
cell
signific
influenc
termin
pegyl
common
strategi
chemic
modif
nucleic
acid
aptam
resist
renal
clearanc
aptam
improv
bind
affin
gener
modif
base
aptam
singl
strand
dna
ggtggtggtggttgtggtggtggtgg
bind
nucleolin
protein
express
surfac
cancer
cell
recent
research
shown
nbenzylcarboxyamid
modif
figur
aptam
might
select
increas
target
affin
cancer
cell
normal
healthi
cell
signific
influenc
benzyl
could
replac
function
group
naphtyl
triptamino
isobutyl
figur
addit
group
might
increas
affin
aptam
target
tabl
tabl
aptam
deriv
improv
bind
affin
specif
site
strategi
applic
base
nucleosid
nbenzylcarboxyamid
modif
slow
offrat
modifi
aptam
somam
phosphodiest
linkag
phosphorodithio
substitut
benzyl
could
replac
function
group
naphtyl
triptamino
isobutyl
benzyl
could
replac
function
group
naphtyl
triptamino
isobutyl
figur
addit
group
might
increas
affin
aptam
target
tabl
benzyl
could
replac
function
group
naphtyl
triptamino
isobutyl
figur
addit
group
might
increas
affin
aptam
target
tabl
tabl
aptam
deriv
improv
bind
affin
specif
site
strategi
applic
base
nucleosid
nbenzylcarboxyamid
modif
slow
offrat
modifi
aptam
somam
phosphodiest
linkag
phosphorodithio
substitut
benzyl
could
replac
function
group
naphtyl
triptamino
isobutyl
base
modif
also
made
signific
advanc
give
aptam
proteinlik
function
somam
slow
offrat
modifi
aptam
display
improv
bind
affin
bind
kinet
particular
slow
offrat
compar
tradit
aptam
also
inclus
modif
librari
significantli
increas
select
hit
rate
power
kind
base
phosphodiest
linkag
phosphorodithio
substitut
benzyl
could
replac
function
group
naphtyl
triptamino
isobutyl
base
modif
also
made
signific
advanc
give
aptam
proteinlik
function
somam
slow
offrat
modifi
aptam
display
improv
bind
affin
bind
kinet
particular
slow
offrat
compar
tradit
aptam
also
inclus
modif
librari
significantli
increas
select
hit
rate
power
kind
base
modif
demonstr
discoveri
nucleotid
somam
bind
pmoll
bind
affin
exhibit
littl
nucleas
degrad
incub
human
serum
nucleic
acid
aptam
much
smaller
antibodi
recent
year
mani
studi
crystal
xray
diffract
analysi
aptam
complex
aptam
enzym
effect
method
develop
modifi
aptam
higher
affin
select
accord
crystal
structur
autotaxin
atx
plasma
lysophospholipas
hydrolyz
lysophosphatidylcholin
lpc
gener
lysophosphatid
acid
lpa
dna
aptam
inhibitor
atx
nureki
cowork
investig
crystal
structur
atx
complex
result
show
inhibit
activ
atx
prevent
bind
lpc
substrat
hydrophob
pocket
atx
could
occupi
inhibitor
occlud
hydrophob
pocket
thu
research
introduc
hydrophob
group
pmethyl
pisopropyl
backbon
phosphat
result
respect
activ
ic
valu
lpc
nm
respect
potent
nm
result
suggest
modif
aim
occlud
hydrophob
pocket
could
significantli
increas
inhibitori
activ
success
modif
base
crystal
structur
inform
nucleic
acid
aptam
wide
use
biotechnolog
biomed
purpos
high
resolut
structur
inform
aptamerligand
complex
could
help
reveal
fundament
aspect
nucleic
acid
fold
nucleic
acidsmal
molecul
interact
structur
inform
aptam
aptamerligand
complex
constitut
start
point
ration
function
direct
chemic
modif
duchardtfern
e
et
al
report
nmr
reson
assign
rna
aptam
bind
fluoresc
ligand
tetramethylrhodamin
tmr
complex
ligand
start
point
highresolut
structur
determin
use
nmr
spectroscopi
solut
report
indic
nmr
guid
aptam
optim
could
option
strategi
aptam
improv
bind
affin
bind
affin
specif
unmodifi
nucleic
acid
aptam
sometim
insuffici
success
implement
therapeut
agent
compar
monoclon
antibodi
postselex
optim
one
bndu
one
napdu
somam
led
improv
bind
inhibit
activ
greater
result
lead
somam
subnanomolar
affin
k
nm
potenc
ic
nm
phosphorodithio
walk
strategi
anoth
option
figur
report
applic
substitut
singl
nucleotid
nucleic
acid
aptam
could
significantli
improv
target
bind
affin
nanomolar
picomolar
xray
cocryst
structur
complex
reveal
local
inducedfit
fold
aptam
lead
increas
target
interact
structur
determin
use
nmr
spectroscopi
solut
report
indic
nmr
guid
aptam
optim
could
option
strategi
aptam
improv
bind
affin
bind
affin
specif
unmodifi
nucleic
acid
aptam
sometim
insuffici
success
implement
therapeut
agent
compar
monoclon
antibodi
postselex
optim
one
bndu
one
napdu
somam
led
improv
bind
inhibit
activ
greater
result
lead
somam
subnanomolar
affin
kd
nm
potenc
nm
phosphorodithio
walk
strategi
anoth
option
figur
report
applic
substitut
singl
nucleotid
nucleic
acid
aptam
could
significantli
improv
target
bind
affin
nanomolar
picomolar
xray
cocryst
structur
complex
reveal
local
inducedfit
fold
aptam
lead
increas
target
interact
worth
note
effect
pso
substitut
see
section
predict
sinc
pso
backbon
modif
chiral
chemic
synthesi
pso
worth
note
effect
pso
substitut
see
section
predict
sinc
pso
backbon
modif
chiral
chemic
synthesi
pso
use
phosphoramidit
methodolog
typic
result
mixtur
diastereoisom
fairli
limit
influenc
affin
improv
promis
deriv
achir
repres
class
close
relat
mimic
natur
nucleic
acid
review
introduc
gener
solid
phase
synthesi
method
nucleic
acid
aptam
addit
number
chemic
modif
dna
rna
aptam
summar
among
modif
shown
figur
end
pegyl
resist
renal
clearanc
end
cap
strategi
resist
nucleas
degrad
invert
thymidin
commonli
use
strategi
recent
studi
two
method
use
aptam
diseas
therapi
ongo
complet
clinic
trial
review
introduc
gener
solid
phase
synthesi
method
nucleic
acid
aptam
addit
number
chemic
modif
dna
rna
aptam
summar
among
modif
shown
figur
pegyl
resist
renal
clearanc
cap
strategi
resist
nucleas
degrad
invert
thymidin
commonli
use
strategi
recent
studi
two
method
use
aptam
diseas
therapi
ongo
complet
clinic
trial
nucleobas
phosphodiest
linkag
modif
improv
target
bind
affin
also
optim
properti
aptam
excitingli
establish
technolog
provid
opportun
gener
nucleic
acid
aptam
substanti
improv
affin
somam
strategi
singl
substitut
without
neg
affect
specif
technolog
also
provid
crucial
insight
could
significantli
acceler
develop
nucleic
acid
aptamerbas
therapeut
clinic
applic
develop
postselex
modif
nucleic
acid
aptam
inher
physicochem
characterist
metabol
instabl
insuffici
bind
affin
rapid
renal
filtrat
nucleic
acid
aptam
improv
constantli
provid
strong
impetu
develop
nucleic
acid
aptam
therapeut
purpos
tabl
nucleobas
phosphodiest
linkag
modif
improv
target
bind
affin
also
optim
properti
aptam
excitingli
establish
technolog
provid
opportun
gener
nucleic
acid
aptam
substanti
improv
affin
somam
strategi
singl
substitut
without
neg
affect
specif
technolog
also
provid
crucial
insight
could
significantli
acceler
develop
nucleic
acid
aptamerbas
therapeut
clinic
applic
develop
postselex
modif
nucleic
acid
aptam
inher
physicochem
characterist
metabol
instabl
insuffici
bind
affin
rapid
renal
filtrat
nucleic
acid
aptam
improv
constantli
provid
strong
impetu
develop
nucleic
acid
aptam
therapeut
purpos
tabl
phosphorodithio
substitut
